Bisphosphonates for Postmenopausal Osteoporosis

Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism: Seventh Edition

Volumn , Issue , 2009, Pages 237-241

  Papapoulos, Socrates E ^a  

^a Department of Endocrinology nnd Metabolic Diseuses   (Netherlands)

Author keywords

Alendronate; Bisphosphonates; Clodronate; Ibandronate; Nonvertebral fractures; Pamidronate; Risedronate; Vertebral fractures; Zoledronate

Indexed keywords

EID: 84889486718     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470623992.ch49     Document Type: Chapter

References (42)

1. Russell RGG, Watts NB, Ebetino FH, Rogers MJ 2008 Macha-nisms of action of bisphosphonates: Similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19:733-759.
2. Papapoulos SE 2006 Bisphosphonate actions: Physical chemistry revisited. Bone 38:613-616.
3. Cremers SC, Pillai G, Papapoulos SE 2005 Pharmacokinetics/pharmacodynamics of bisphosphonates: Use for optimisation of intermittent therapy for osteoporosis. Clin Pharmacokinet 44:551-570.
4. Rogers MJ 2004 From molds and macrophages to mevalonate: A decade of progress in understanding the molecular mode of action of bisphsposphonates. Calcif Tissue Int 75:451-161.
5. Brumsen C, Papapoulos SE, Lips P, Geelhoed-Duijvestijn PHLM, Hamdy NAT, Landman JO, McCloskey EV, Netelenbos JC, Pau-wels EKJ, Roos JC, Valentijn RM, Zwinderman AH 2002 Daily oral pamidronate in women and men with osteoporosis: A 3-year randomized placebo-controlled clinical trial with a 2-year open extension. J Bone Miner Res 17:1057-1064.
6. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535-1541.
7. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. JAMA 280:2077-2082.
8. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH III, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD 1999 Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282:1344-1352.
9. Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R 2000 Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11:83-91.
10. Chesnut CH, Ettinger MP, Miller PD, Baylink DJ, Emkey R, Harris ST, Wasnich RD, Watts NB, Schimmer RC, Recker RR 2004 Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241-1249.
11. McCloskey E, Selby P, Davies M, Robinson J, Francis RM, Adams J, Kayan K, Beneton M, Jalava T, Pylkkanen L, Kenraali J, Aro-puu S, Kanis JA 2004 Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: Results of a double-blind, placebo-controlled 3-year study. J Bone Miner Res 19:728-736.
12. Cranney A. Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C; Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group 2002 Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 23:570-578.
13. Wells G, Cranney A. Peterson J, Boucher M, Shea B, Robinson V, Coyle D, Tugwell P 2008 Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 23:CD004523.
14. Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, Coyle D, Tugwell P 2008 Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 23:CD001155.
15. Felsenberg D, Miller P, Armbrecht G, Wilson K, Schimmer RC, Papapoulos SE 2005 Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis. Bone 37:651-654.
16. Black DM. Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, Nevitt MC, Suryawanshi S, Cummings SR; Fracture Intervention Trial 2000 Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 85:4118-4124.
17. Roux C, Seeman E, Eastell R, Adachi J, Jackson RD, Felsenberg D, Songcharoen S, Rizzoli R, Di Munno O, Horlait S, Valent D, Watts NB 2004 Efficacy of risedronate on clinical vertebral fractures within six months. Curr Med Res Opin 20:433-139.
18. Papapoulos SE. Quandt SA, Liberman UA, Hochberg MC, Thompson DE 2005 Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women. Osteoporos Int 16:468-474.
19. Nguyen ND, Eisman JA, Nguyen TV 2006 Anti-hip fracture efficacy of biophosphonates: A Bayesian analysis of clinical trials. J Bone Miner Res 21:340-349.
20. Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C 2004 The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15:1003-1008.
21. Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, Silverman S 2006 Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: Relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81:1013-1022.
22. Schnitzer T, Bone HG, Crepaldi G, Adami S, McClung M, Kiel D, Felsenberg D, Recker RR, Tonino RP, Roux C, Pinchera A, Foldes AJ. Greenspan SL, Levine MA, Emkey R, Santora AC II, Kaur A, Thompson DE, Yates J, Orloff JJ 2000 Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) 12:1-12.
23. Brown JP, Kendler DL, McClung MR, Emkey RD, Adachi JD, Bolognese MA, Li Z, Balske A, Lindsay R 2002 The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 71:103-111.
24. Adachi JD. Rizzoli R, Boonen S, Li Z, Meredith MP, Chesnut CH III 2005 Vertebral fracture risk reduction with risedronate in postmenopausal women with osteoporosis: A meta-analysis of individual patient data. Aging Clin Exp Res 17:150-156.
25. Papapoulos SE, Schimmer RC 2007 Changes in bone remodelling and antifracture efficacy of intermittent bisphosphonate therapy: Implications from clinical studies with ibandronate. Ann Rheum Dis 66:853-858.
26. Reginster JY, Adami S, Lakatos P, Greenwald M, Stepan JJ, Silverman SL, Christiansen C, Rowell L. Mairon N, Bonvoisin B, Drezner MK, Emkey R. Felsenberg D, Cooper C, Delmas PD, Miller PD 2006 Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 65:654-661.
27. Eisman JA, Civitelli R, Adami S, Czerwinski E, Recknor C, Prince R, Reginster JY, Zaidi M, Felsenberg D, Hughes C, Mairon N, Masanauskaite D, Reid DM, Delmas PD, Recker RR 2008 Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheumatol 35:488-197.
28. Black DM, Delmas PD, Eastell R, Reid IR. Boonen S, Cauley JA, Cosman F, Lakatos P. Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR; HORIZON Pivotal Fracture Trial 2007 Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809-1822.
29. Lyles KW, Colón-Emeric CS, Magaziner JS, Adachi JD. Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S; HORIZON Recurrent Fracture Trial 2007 Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799-1809.
30. Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA 2004 Alendronate phase III osteoporosis treatment study group. N Engl J Med 350:1189-1199.
31. Mellstròm DD, Sorensen OH, Goemaere S, Roux C, Johnson TD, Chines AA 2004 Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 75:462-168.
32. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satlerfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR; FLEX Research Group 2006 Effects of continuing or stopping alendronate after 5 years of treatment: The Fracture Intervention Trial Long-term Extension (FLEX): A randomized trial. JAMA 296:2927-2938.
33. Allen MR, Iwata K, Phipps R, Burr DB 2006 Alterations in canine vertebral bone turnover, microdamage accumulation, and biome-chanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate. Bone 39:872-879.
34. Chapurlat RD, Arlot M, Burt-Pichat B, Chavassieux P, Roux JP, Portero-Muzy N, Delmas PD. Chapurlat RD, Arlot M, Burt-Pichat B, Chavassieux P, Roux J-P, Portero-Muzy N, Delmas PD 2007 Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: A bone biopsy study. J Bone Miner Res 22:1502-1509.
35. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY 2005 Severely suppressed bone turnover: A potential complication of alendronate therapy. J Clin Endocrinol Metab 90:1294-1301.
36. Goh SK, Yang KY, Koh JS, Wong MK, Chua SY, Chua DT, Howe TS 2007 Subtrochanteric insufficiency fractures in patients on alendronate therapy: A caution. J Bone Joint Surg Br 89:349-353.
37. Kwek EB, Goh SK, Koh JS, Png MA, Howe TS 2008 An emerging pattern of subtrochanteric stress fractures: A long-term complication of alendronate therapy? Injury 39:224-231.
38. Bauer DC, Black DM, Garnero P, Hochberg M, Ott S, Orloff J, Thompson DE, Ewing SK, Delmas PD; Fracture Intervention Trial Study Group 2004 Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: The fracture intervention trial. J Bone Miner Res 19:1250-1258.
39. Obermaier-Pietsch CB, Marin F, McCloskey E, Hadji P, Simoes ME, Barker C, Oertel H, Nickelsen TN, Boonen S 2007 Effects of prior antiresorptive therapy on markers of bone formation after 6 months of teriparatide treatment in postmenopausal women with osteoporosis: Results from the Eurofors trial. Calcif Tissue Int 80(Suppl 1):S137.
40. McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J 2007 Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone 41:122-128.
41. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S, McCauley LK, McGowan J, McKee MD, Mohla S, Pendrys DG, Raisz LG, Ruggiero SL, Shafer DM, Shum L, Silverman SL, Van Poznak CH, Watts N, Woo SB, Shane E; American Society for Bone and Mineral Research 2007 Bisphosphonate-associated osteonecrosis of the jaw: Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22:1479-1491.
42. Rizzoli R, Burlet N, Cahall D, Delmas PD, Eriksen EF, Felsenberg D, Grbic J, Jontell M, Landesberg R, Laslop A, Wollenhaupt M, Papapoulos S, Sezer O, Sprafka M, Reginster JY 2008 Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone 42:841-847.